China smartphone shipments slumped in June on inventory overhang: Jefferies
Michael Egholm, President and CEO of Standard Biotools Inc. (NASDAQ:LAB), recently executed a sale of common stock valued at approximately $5,150. The transaction, dated May 23, involved the sale of 5,473 shares at a weighted average price of $0.941 per share. The shares were sold to cover tax obligations arising from the vesting of restricted stock units granted to Egholm earlier in March 2025. Following the sale, Egholm retains ownership of 2,741,191 shares of the company.Standard Biotools, with a market capitalization of $412 million, has shown significant price volatility this year, with shares trading between $0.92 and $2.65. According to InvestingPro analysis, the company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 6.12. Despite challenging market conditions reflected in its -57% one-year return, the company’s financial health score remains favorable.Discover more insights about Standard Biotools and 1,400+ other stocks through comprehensive InvestingPro Research Reports, featuring detailed analysis and actionable intelligence for smarter investing decisions.
In other recent news, Standard Biotools Inc. reported its financial results for the first quarter of 2025, revealing a net loss that fell short of analyst expectations. The company posted an earnings per share (EPS) of -$0.07, missing the forecasted -$0.06. Revenue also underperformed, coming in at $40.8 million compared to the anticipated $45.6 million, marking a 10% year-over-year decline. Despite these setbacks, the company has set its full-year revenue guidance for 2025 between $165 million and $175 million. Standard Biotools also introduced several new products, with strong demand noted for its Hyperion XDI systems. In terms of analyst activity, there were no specific upgrades or downgrades reported. The company continues to explore strategic mergers and acquisitions as part of its long-term growth strategy. Additionally, Standard Biotools maintains a solid cash position of $261 million with no material debt.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.